AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: FDA

Safest SARMs For Muscle Growth 2025: CrazyBulk Introduces Effective SARMs For Bulking, Cutting and Strength in USA.

Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective Androgen Receptor Modulators (SARMs) have emerged as a promising alternative to traditional anabolic steroids, offering similar benefits with reduced side effects. However, the safety and legality of SARMs vary, making it crucial for enthusiasts to exercise caution when choosing wisely.

RESEARCH SHOWS EARLY CANCER CELLS CAN BE RAPIDLY DETECTED THROUGH ELECTRONIC SEMICONDUCTORS

CLEVELAND, July 15, 2025 /PRNewswire/ -- IdentifySensors Biologics, a leader in digital diagnostic technologies, has demonstrated that its electronic biosensors used to detect pathogens...

Les Laboratoires de Chalk River deviennent les premiers laboratoires certifiés BPL au Canada à offrir des études radiopharmaceutiques précliniques

Après avoir passé avec succès une vérification par le CCN, les LNC sont désormais prêts à mener des études précliniques pour l’industrie radiopharmaceutique en pleine croissance en tant que laboratoire qui respecte les bonnes pratiques de laboratoire (BPL)
Après avoir passé avec succès une vérification par le CCN, les LNC sont désormais prêts à mener des études précliniques pour l’industrie radiopharmaceutique en pleine croissance en tant que laboratoire qui respecte les bonnes pratiques de laboratoire (BPL)

Chalk River Laboratories Becomes First GLP-Certified Laboratory in Canada to Offer Pre-Clinical Radiopharmaceutical Studies

Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory
Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual...

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also...

Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)

Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)

Ascentage Pharma Announces Pricing of Top-Up Placement

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)(the “Offshore Placement”), for aggregate gross proceeds of approximately HKD1,509.2 million (or approximately US$192.3 million based on exchange rate of 1 USD to 7.85 HKD), before deducting placing fees and other offering expenses. The Offshore Placement, which was oversubscribed by eight times, is expected to close on July 17, 2025.

HIMS FRAUD CLASS ACTION: Hims & Hers Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by August 25 Legal...

Hims & Hers Health, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings...

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026MCO-010 BLA for retinitis pigmentosa is eligible for priority review...

Microcrystalline Cellulose (MCC) Market worth $1.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market  by Source (Wood based, non-wood based), by Application (Food & Beverage,...

Microcrystalline Cellulose (MCC) Market worth $1.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ -- The report "Microcrystalline Cellulose Market  by Source (Wood based, non-wood based), by Application (Food & Beverage,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA